secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016376
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q1 revenue drops 97% to $0.6M; net loss of $5.8M vs prior-year profit
--------------------------------------------------------------------------------

- Revenue of $0.6M, down from $22.7M a year ago due to lower COVID-19 test demand.
- Net loss of $5.8M ($0.20 diluted EPS loss) vs net income of $11.7M ($0.34 EPS) in Q1 2022.
- Operating loss of $10.0M vs operating income of $9.8M; adjusted EBITDA loss of $7.2M.
- Cash, cash equivalents, and marketable securities of $75.3M as of March 31, 2023.
- Co-Dx PCR Home platform clinical trials on track; FDA submission expected by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223016376/0001493152-23-016376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223016376/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer